Detailed Narrative
Q4 & FY25 Financial Performance Overview
Bodal Chemicals reported a robust Q4 FY25, with consolidated revenue reaching ₹453 crores, marking a 14% year-on-year growth. Consolidated EBITDA surged by 62% year-on-year to ₹50 crores, achieving a margin of 10.9%. For the full fiscal year FY25, total consolidated revenue stood at ₹1,757 crores, a 24% increase from FY24, and consolidated PAT saw a significant jump of 186% to ₹18.5 crores. This growth was primarily driven by improved volumes and better realizations across various business segments.
Segmental Performance and Outlook
The dye intermediate business recorded ₹667 crores in revenue for FY25, growing 36% YoY, with Q4 revenue at ₹160 crores. Dyestuffs revenue for FY25 was ₹498 crores (6% YoY growth), and ₹125 crores for Q4 (6.5% YoY growth), with management expecting 10-15% improvement in FY26. Basic chemicals revenue for FY25 was ₹92 crores (11% YoY growth), though Q4 saw a 9% QoQ degrowth to ₹19 crores due to a plant shutdown. The Chlor-Alkali business demonstrated strong performance with ₹335 crores revenue in FY25 (25% YoY growth) and ₹91 crores in Q4 (34% YoY growth), with a projected 5-10% growth for FY26.
TCCA Business Turnaround Post Anti-Dumping Duty
A significant positive development is the implementation of anti-dumping duty on TCCA imports from China for five years, effective March 7, 2025. This is expected to turn around the TCCA business, which previously faced challenges from imported goods. For FY26, the company anticipates producing at least 4,000 metric tons of TCCA-90, contributing approximately ₹70 crores to the top-line with improved margins. TCCA prices have already increased from around $1/kg to ₹160+/kg post-duty.
Benzene Derivatives and Future Growth
The Saykha benzene derivatives project, while contributing to the top-line in Q4 FY25, still faces margin pressure due to stiff competition and slower demand, particularly from the paracetamol industry operating at 50% utilization. The unit's utilization was 25-30% in Q4 FY25, currently around 45%, with a target to reach 50-60% in the coming months and an optimum 80% utilization for the full year. Management believes 65-70% utilization, coupled with 8-10% pricing improvement, will make the segment EBITDA positive.
Capital Allocation and Debt Management
The company plans to reduce its debt by ₹120-150 crores during the current year through scheduled repayments and proceeds from land sales. The blended interest rate on existing debt is approximately 9.25%. For FY26, the focus remains on increasing utilization and improving margins across existing divisions, with no major CAPEX planned. However, a small expansion in Chlor-Alkali, costing less than ₹10 crores, is being considered to add ₹60-70 crores in annual revenue.
Subsidiary Operations and Future Outlook
The Turkish subsidiary, Sener Boya, reported a ₹2.34 crore loss in Q4 FY25 due to hyperinflation, though currency devaluation has stabilized. Management indicated that closing the subsidiary would be easy due to its asset-light nature and small staff, with direct exports being a viable alternative. For FY26, Bodal Chemicals targets a top-line of ₹1,900 crores plus and an EBITDA margin of 11-12%, driven by improved performance in TCCA, benzene derivatives, and Chlor-Alkali.